Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACP1 | P24666 | 14/20 | 0.65 |
| ▸ | ABCG2 | Q9UNQ0 | 5/20 | 0.62 |
| ▸ | ABCB1 | P08183 | 4/20 | 0.53 |
| ▸ | ABCC1 | P33527 | 2/20 | 0.52 |
| ▸ | ESR1 | P03372 | 1/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6001831 | 0.81 | KDR (0.45) | ACP1ABCG2ABCB1ESR1ESR2 | |
| SCHEMBL6001826 | 0.79 | ACP1 (0.76) | ACP1ABCG2ABCB1ABCC1 | |
| SCHEMBL6001965 | 0.78 | ACP1 (0.61) | ACP1ABCG2ABCB1 | |
| SCHEMBL5802621 | 0.77 | ACP1 (0.71) | ACP1ABCG2ABCB1 | |
| SCHEMBL5799650 | 0.77 | ACP1 (0.71) | ACP1ABCG2ABCB1ABCC1 | |
| SCHEMBL4855755 | 0.76 | CYP19A1 (0.60) | ACP1ABCG2 | |
| SCHEMBL5999859 | 0.74 | LMNA (0.51) | ACP1ESR1ESR2 | |
| SCHEMBL22201279 | 0.73 | ABCG2 (0.85) | ACP1ABCG2ABCB1ABCC1 | |
| SCHEMBL6001853 | 0.73 | ACP1 (0.64) | ACP1ABCG2ABCB1 | |
| SCHEMBL17688814 | 0.71 | ACP1 (1.00) | ACP1ABCG2ABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060128702-A1 | Heterocyclic and bicyclic compounds, compositions and methods | REDDY US THERAPEUTICS, INC. | 2006-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128702-A1 | Heterocyclic and bicyclic compounds, compositions and methods | HPSE, ENGASE, UGCG | ACP1 429/4885ABCG2 2694/4885ABCB1 2698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.